43rd week of 2015 patent applcation highlights part 26 |
Patent application number | Title | Published |
20150299205 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE - The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. | 2015-10-22 |
20150299206 | SMALL MOLECULE CFTR CORRECTORS - Novel CFTR corrector compounds that are effective in rescuing halide efflux, delF508-CFTR protein processing, and apical functional chloride ion transport in a cell are provided. Also provided are methods for treating protein folding disorders (e.g., cystic fibrosis). The methods include administering a CFTR corrector compound or pharmaceutically acceptable salt or prodrug thereof. Methods of rescuing halide efflux in a cell, correcting a processing defect of a delF508-CFTR protein in a cell, and correcting functional delF508-CFTR chloride channels in a cell are also provided. | 2015-10-22 |
20150299207 | SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL)PYRIDIN-3-YL)-3,4-DIHYDROPYR- AZINO[2,3-b]PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF - Provided herein are formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one. | 2015-10-22 |
20150299208 | SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2-YL)PYRIDIN-3-YL)-1-((TRANS)-4-METHOXYCYCLOHEXYL)-- 3,4-DIHYDROPYRAZINO[2,3-b]PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF - Provided herein are formulations, processes, solid forms and methods of use relating to 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one. | 2015-10-22 |
20150299209 | SOLID FORMS OF 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL)PYRIDIN-3-YL)-3,4-DIHYDROPYR- AZINO[2,3-b]PYRAZIN-2(1H)-ONE, COMPOSITIONS THEREOF AND METHODS OF THEIR USE - Provided herein are formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one. | 2015-10-22 |
20150299210 | Benzodiazepine Bromodomain Inhibitor - Benzodiazepine compounds of formula (I) | 2015-10-22 |
20150299211 | MDM2 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME - Inhibitors of MDM2 and MDM2-related proteins and compositions containing the same are disclosed. Methods of using the MDM2 inhibitors in the treatment of diseases and conditions wherein inhibition of an interaction between p53 and MDM2 provides a benefit, like cancers, also are disclosed. | 2015-10-22 |
20150299212 | Tricyclic Lactams for Use in HSPC-Sparing Treatments for RB-Positive Abnormal Cellular Proliferation - This invention is in the area of tricyclic lactam compounds for and methods of treating selected Rb-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities. In one aspect, treatment of select Rb-positive cancers is disclosed using specific compounds disclosed herein. In certain embodiments, the compounds described herein act as selective cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects. | 2015-10-22 |
20150299213 | ANTIVIRAL COMPOUNDS - The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 2015-10-22 |
20150299214 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND - The present invention provides a heterocyclic compound represented by the following formula (I), wherein X | 2015-10-22 |
20150299215 | SPIRO RING COMPOUND AS HEPATITIS C VIRUS (HCV) INHIBITOR AND USES THEREOF - A compound of formula (I) or a stereoisomer, a geometric isomer. a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof is provided, which can be used for treating HCV infection or a HCV disorder. Also a pharmaceutical composition comprising the compound and the use of the compound and the pharmaceutical composition thereof are provided, which can also be used for treating HCV infection or a HCV disorder. | 2015-10-22 |
20150299216 | METHOD FOR PREPARING ANHYDROUS SUGAR ALCOHOL - The present invention relates to a method for preparing anhydrous sugar alcohol, and more particularly, to a cheap and highly efficient method for preparing anhydrous sugar alcohol having a high final purity of at least 99%, and having good ion content, pH, conductivity, and color properties. According to the method, a hydrogenated sugar is dehydrated so as to be transformed into anhydrous sugar alcohol, and a series of processes including distillation, crystallization, decoloration, and ion exchange resin treatment are conducted. | 2015-10-22 |
20150299217 | ARTEMISININ DERIVATIVES, METHODS FOR THEIR PREPARATION AND THEIR USE AS ANTIMALARIAL AGENTS - Derivatives of the antimalarial agent artemisinin, compositions comprising the derivatives, methods for preparing the derivatives, and their uses in pharmaceutical compositions intended for the treatment of parasitic infections are provided. Methods are provided for the production of artemisinin derivatives via functionalization of positions C7 and C6a, and optionally, in conjunction with modifications at positions C10 and C9, via chemoenzymatic methods. Recombinant cytochrome P450 polypeptides are also provided for use in the methods. The artemisinin derivatives can be used for the treatment of malaria and other parasitic infections, alone or in combination with other antiparasitic drugs. | 2015-10-22 |
20150299218 | Heterocyclic Compounds As Inhibitors Of The Sodium Iodide Symporter - The invention relates to new compounds of formula (I): | 2015-10-22 |
20150299219 | BICYCLIC PYRAZOLONE COMPOUNDS AND METHODS OF USE - The present invention provides substituted bicyclic pyrazolone compounds, which are used to inhibit or modulate the activity of receptor tyrosine kinases, especially Axl, Mer, c-Met and Ron. The invention also provides pharmaceutical compositions comprising the compound disclosed herein, and a method of preventing, treating or lessening the severity of a proliferative disorder in a patient with the compounds or the pharmaceutical compositions disclosed herein. | 2015-10-22 |
20150299220 | NOVEL PYRAZINE DERIVATIVES AS CB2 RECEPTOR AGONISTS - The invention relates to a compound of formula (I) wherein R | 2015-10-22 |
20150299221 | MACROCYCLIC PURINES FOR THE TREATMENT OF VIRAL INFECTIONS - This invention relates macrocyclic purine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections. | 2015-10-22 |
20150299222 | COCRYSTAL OF PIPERACILLIN SODIUM AND SULBACTAM SODIUM AND PREPARATION METHOD THEREOF, AS WELL AS PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF - Provided in the present invention are a cocrystal of piperacillin sodium and sulbactam sodium and preparation method thereof, as well as pharmaceutical compositions containing the same and uses thereof in treating infections caused by drug-resistant bacteria, such as a “super bacterium” producing NDM-1 and the like. The cocrystal of piperacillin sodium and sulbactam sodium contains diffraction angles of 14.24°, 16.58°, 16.79°, 17.77°, 19.20°, 20.21°, 20.39°, 23.06°, 27.86° and 32.16° represented by 2θ in an X-ray powder diffraction analysis spectrum. | 2015-10-22 |
20150299223 | 2-SUBSTITUTED CEPHEM COMPOUNDS - The present invention relates to 2-substituted cephem compounds of Formula (I) having a quaternary ammonium group on the 3-side chain, preferably together with a cathechol group, or pharmaceutically acceptable salts thereof, which exhibit potent antimicrobial spectrum against a variety of bacteria including Gram negative bacteria and/or Gram positive bacteria, corresponding pharmaceutical compositions, methods of making, treatment methods for bacterial infections or uses thereof. | 2015-10-22 |
20150299224 | INHIBITORS OF IRAK4 ACTIVITY - The present invention relates to compounds which modulate interleukin-1 (IL-1) receptor-associated kinase 4 (IRAK4) and are useful in the prevention or treatment of inflammatory, cell proliferative and immune-related conditions and diseases. Specifically, provided herein are inhibitors of IRAK4 of Formula I and pharmaceutical compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases. | 2015-10-22 |
20150299225 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION - The present application relates to compounds and methods for treating pain and other conditions related to TRPV3. | 2015-10-22 |
20150299226 | TUNABLE METAL-ORGANIC FRAMEWORKS - A method, system, and apparatus for tunable metal-organic frameworks comprises a plurality of metallic ions, a plurality of organic linking anions that connect adjacent metallic ions of the plurality of metallic ions, and a plurality of cations connected to the plurality of organic linking anions, wherein the plurality of cations are selected from the group consisting of inorganic cations, organic cations, imidazolium based cations, pyridinium based cations, and cationic organic polymers and coordinated ligands. | 2015-10-22 |
20150299227 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS - The present invention relates to 4-pyridinone compounds which are inhibitors of catechol O-methyltransferase (COMT), and are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which COMT enzyme is involved. The present invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which COMT is involved. | 2015-10-22 |
20150299228 | AZOCARBONYL-FUNCTIONALIZED SILANES - Azocarbonyl-functionalized silanes of formula I | 2015-10-22 |
20150299229 | PROCESS FOR THE REMOVAL AND RETURN OF A CATALYST TO A LIQUID PHASE MEDIUM - A process for the selective removal of a component from a liquid phase and subsequently returning the component to a liquid phase is disclosed. A novel compound of formula (I) [SUP]-[[L]-[G]]a (I) in which L is a linking group, G is an aryl group having a leaving group LG selected from Cl, Br, I, sulfonate such as triflate, a diazo group, a nitrile, an ester and an alkoxy group and substituent Q is selected from H, NR2, OR, C02R, F, Cl, N02 CN and SUP is a support having a plurality of groups -[L]-[G] bound to the support is contacted with the liquid phase to bind the component to the compound I thereby forming a captured component which is separated from and may be returned to the liquid phase. The compound I is especially useful in binding homogeneous catalysts to remove it from a reaction medium and selectively returning the catalyst to the reaction medium at a later stage. The compound is particularly useful for cross-coupling reactions, for example in Suzuki reactions. | 2015-10-22 |
20150299230 | Novel Prodrugs And Methods Of Use Thereof - The invention relates to compounds of use as targeted cytotoxic agents and methods of use thereof. In particular, the invention relates to prodrugs that are substantially resistant to human AKR1C3 enzyme metabolism, methods of cell ablation using said compounds and methods of treatment of cancer and other hyperproliferative disorders using said compounds. | 2015-10-22 |
20150299231 | A PROCESS FOR THE PREPARATION OF ACYLPHOSPHANES - The present invention provides a process for the preparation of mono- and bisacylphosphanes based on formula (I): | 2015-10-22 |
20150299232 | GUANINE ANALOGS AS TELOMERASE SUBSTRATES AND TELOMERE LENGTH AFFECTORS - This invention relates to compounds useful for inhibiting telomere elongation. More specifically, the invention provides nucleotide analogs that are incorporated into telomeres by telomerase thereby inhibiting elongation of telomeres. The compounds are useful in treating cancer and other cell proliferative diseases. | 2015-10-22 |
20150299233 | COMPOSITIONS AND METHODS COMPRISING RHENIUM FOR THE TREATMENT OF CANCERS - Compositions and methods comprising rhenium are provided. In some embodiments, the rhenium compounds comprise a bidentate ligand. In some embodiments, the rhenium compounds are used in method for treating cancer. | 2015-10-22 |
20150299234 | COMPLEXES OF PHOSPHINE LIGANDS COMPRISING A CARBA-CLOSO-DODECABORATE SUBSTITUENT - This invention relates to complexes comprising phosphine ligands comprising a carbo-closo-dodecaborate substituent and transition metals as well as their use in catalytic reactions. | 2015-10-22 |
20150299235 | METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS - Synthetic methods for the in-situ formation of olefin metathesis catalysts are disclosed, as well as the use of such catalysts in metathesis reactions of olefins and olefin compounds. In one aspect, a method is provided for synthesizing an organometallic compound of the formula | 2015-10-22 |
20150299236 | Z-SELECTIVE METATHESIS CATALYSTS - A novel chelated ruthenium-based metathesis catalyst bearing an N-2,6-diisopropylphenyl group is reported and displays near-perfect selectivity for the Z-olefin (>95%), as well as unparalleled TONs of up to 7,400, in a variety of homodimerization and industrially relevant metathesis reactions. This derivative and other new catalytically-active species were synthesized using an improved method employing sodium carboxylates to induce the salt metathesis and C—H activation of these chelated complexes. All of these new ruthenium-based catalysts are highly Z-selective in the homodimerization of terminal olefins. | 2015-10-22 |
20150299237 | ANTI-TUMOR BIVALENT PLATINUM COMPLEX AND PREPARATION METHOD FOR COMPLEX AND LIGAND OF COMPLEX - Platinum complexes containing 3-ketone cyclobutane 1,1-dicarboxylic acid as leaving group for treating cancers and a preparation method of the complexes, one of the platinum complexes is cis-[3-ketone cyclobutane-1,1-dicarboxylic acid radical.diamineplatinum (II)], GSH-5 for short, the chemical structure formula is expressed by formula (1). The other platinum complex is cis-[3-ketone-cyclobutane-1,1-dicarboxylic acid radica.trans-1,2-cyclohexanediamineplatinum (II)], GSH-6 for short, the chemical structure formula is expressed by formula (2). In the formula (2), two chiral carbon atoms marked with * in the trans-1,2-cyclohexanediamine group are both of R forms or S forms. | 2015-10-22 |
20150299238 | SYNTHESIS AND USE OF PRODRUG COMPLEXES OF COBALT IN POLYMER THERAPEUTICS - Degradable compounds that can be controlled to degrade and can be used for delivery of a cargo component. Cobalt (III) complexes have been exploited as vehicles for molecular complexes. This disclosure describes the use of such complexes as bioconjugation reagents in crosslinking proteins to form particles, PEGylation of proteins, and the synthesis of (bio)polymer-drug conjugates. The Co-based linkages can be designed to respond to internal stimuli, such as changes in pH and reduction potential, or external stimuli, such as applied electromagnetic radiation. Therapeutics are entrapped within these crosslinked particles, covalently attached to the polymer making up the matrix through additional stimuli-responsive linkages, or could comprise the matrix itself. | 2015-10-22 |
20150299239 | NOVEL TRIDENTATE COMPLEXES AND PROCESS OF PRODUCING POLYCARBONATE BY COPOLYMERIZATION OF CARBON DIOXIDE AND EPOXIDE USING THE SAME AS CATALYST - Provided are a complex synthesized from a novel tridentate ligand including an ammonium salt and a process of producing polycarbonate by copolymerization of carbon dioxide and epoxide using the same as a catalyst. A novel tridentate complex may be cheaply prepared as compared to the existing tetradentate complex containing four ammonium salts but have an advantage in that the novel tridentate complex may have an activity at a level similar to that of the existing tetradentate complex by adopting a cis-β conformation. Further, since in the tridentate complex, the number of ammonium salt serving as an initiator is small but the number of vacant sites is large as compared to the tetradentate complex containing four ammonium salts, the tridentate complex may have excellent activity. | 2015-10-22 |
20150299240 | AMPHIPHILIC NANOSHEETS AND METHODS OF MAKING THE SAME - In some embodiments, the present invention provides amphiphilic nanosheets that comprise lamellar crystals with at least two regions: a first hydrophilic region, and a second hydrophobic region. In some embodiments, the amphiphilic nanosheets of the present invention also comprise a plurality of functional groups that are appended to the lamellar crystals. In some embodiments, the functional groups are hydrophobic functional groups that are appended to the second region of the lamellar crystals. In some embodiments, the lamellar crystals comprise α-zirconium phosphates. Additional embodiments of the present invention pertain to methods of making the aforementioned amphiphilic nanosheets. Such methods generally comprise appending one or more functional groups to a stack of lamellar crystals; and exfoliating the stack of lamellar crystals for form the amphiphilic nanosheets. | 2015-10-22 |
20150299241 | METHOD FOR PREPARING HIGHLY PURE DOXORUBICIN - The present invention relates to a method for preparing highly pure doxorubicin. The method comprises the following steps: (1) chromatographing a prepurified doxorubicin solution by using macroporous resin, pre-washing the chromatographed system by using an acidic low concentration aqueous organic solvent, and performing elution by using an acidic high concentration aqueous organic solvent; (2) performing chromatographic separation on eluted components by using a preparative column, so that a highly pure doxorubicin component can be obtained, and the doxorubicin can, if needed, be separated from the aqueous solution by using conventional concentration and crystallization methods in the prior art. The present invention has the advantages such as simplicity, high yield, low cost, and less environmental pollution. The content of the prepared doxorubicin is greater than 99.5%, the content of each impurity is controlled to be lower than 0.10%, and the USP and EP standards are met. | 2015-10-22 |
20150299242 | USE OF HYDROXYCINNAMALDEHYDE GLYCOSIDE DERIVATIVES FOR TREATING GLOMERULONEPHRITIS - The present invention relates to a new use of a cinnamaldehyde derivative of formula (I) for treating glomerulonephritis (GN). Particularly, the present invention discloses that the cinnamaldehyde derivative of formula (I) is effective in treating glomerulonephritis (GN), which can alleviate various symptoms and signs of GN, including reducing proteinuria, serum blood urea nitrogen (BUN), glomerular cell proliferation, and renal macrophage/lymphocyte infiltration, etc. | 2015-10-22 |
20150299243 | 2'-ALKYNYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES - The present invention relates to 2′-Alkynyl Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, R1, R2, R3 and R4 are as defined herein. The present invention also relates to compositions comprising at least one 2′-Alkynyl Substituted Nucleoside Derivative, and methods of using the 2′-Alkynyl Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient. | 2015-10-22 |
20150299244 | TESTOSTERONE DERIVATIVES WITH A CARBOXYALKYL SUBSTITUTION IN POSITION 3 AND USE THEREOF FOR THE PRODUCTION OF LABELLED STEROIDS FOR DETERMINING THE CONCENTRATION OF TESTOSTERONE IN A BIOLOGICAL SAMPLE - A testosterone derivative of formula (I): | 2015-10-22 |
20150299245 | PREPARATION OF BILE ACIDS AND INTERMEDIATES THEREOF - Synthetic methods for preparing deoxycholic acid and intermediates thereof are provided. | 2015-10-22 |
20150299246 | N-SUBSTITUTED INDENOISOQUINOLINES AND SYNTHESES THEREOF - N-Substituted indenoisoquinoline compounds, and pharmaceutical formulations of N-substituted indenoisoquinoline compounds are described. Also described are processes for preparing N-substituted indenoisoquinoline compounds. Also described are methods for treating cancer in mammals using the described N-substituted indenoisoquinoline compounds or pharmaceutical formulations thereof. | 2015-10-22 |
20150299247 | AN IMPROVED PROCESS FOR PREPARATION OF PHYSIOLOGICALLY ACTIVE POLYPEPTIDE COMPLEX - Disclosed is a method for the preparation of a complex in which a physiologically active polypeptide is covalently bonded to an immunoglobulin constant region via a non-peptidyl linker. The method is characterized by the employment of a reducing agent, by which conventional problems of low production yield and modification of the polypeptide can be overcome. The physiologically active polypeptide-non-peptidyl polymer-immunoglobulin constant region complex can be produced with high purity and yield as well as at low cost. Thus, the method is industrially useful. Moreover, by exhibiting a prolonged action profile, the physiologically active polypeptide-non-peptidyl polymer-immunoglobulin constant region complex can be effectively used for developing long-acting formulations of physiologically active polypeptides which have improved drug compliance. | 2015-10-22 |
20150299248 | Multimodal Anion Exchange Matrices - The invention discloses a separation matrix which comprises a plurality of separation ligands, defined by the formula R | 2015-10-22 |
20150299249 | PURIFICATION OF PROTEINS USING HYDROPHOBIC INTERACTION CHROMATOGRAPHY - The present invention is directed to methods for purifying a protein of interest, e.g., an antibody, from a sample comprising the protein of interest and at least one impurity, e.g., an aggregate, by employing a hydrophobic interaction chromatography (HIC) method that allows for binding of both the protein of interest and the at least one impurity under strong binding conditions. The present invention is based, at least in part, on the finding that both flow through and bind-elute techniques can be combined to achieve greater purification and recovery of a protein of interest, e.g., an antibody, under isocratic wash conditions and strong binding conditions. | 2015-10-22 |
20150299250 | MACROCYCLIC COMPOUNDS AND USES THEREOF - The present invention relates to novel macrocyclic compounds of Formula I and their use as novel therapeutic agents for example as novel compounds used in methods of preventing and/or treating a disease, condition or state in a subject associated with dysregulation of protease activity and/or dysregulation of proteosome activity | 2015-10-22 |
20150299251 | Skin Care Compositions and Methods Comprising Selective Agonists of Melanocortin 1 Receptor - Short tri- and tetrapeptides according to the following Formula I Ar(CH | 2015-10-22 |
20150299252 | COMPOSITIONS AND METHODS FOR MODULATING INNATE AND ADAPTIVE IMMUNE SYSTEMS - Compositions and methods useful in modulating the innate and adaptive immune systems in a subject, including activation of natural killer (NK) cells and/or CD8+ cytotoxic T lymphocytes. The method typically comprises: administering to the subject a composition comprising a therapeutic peptide or a multivalent structured polypeptide comprising multiple copies of the therapeutic peptide described herein in an amount sufficient to increase activity of NK cells and/or CD8+ cytotoxic T lymphocytes in the subject. Preferred therapeutic compositions comprise a carrier; at least one agent selected from the group consisting of: an anti-inflammatory agent, a cytotoxic T cell proliferation agent, or a NK cell proliferation agent; and a therapeutic peptide or a multivalent structured polypeptides of the invention. In certain embodiments, the composition further comprises an immunoglobulin admixed therewith in an amount sufficient to enhance passive immunoprotection in the subject. In other embodiments, the compositions are administered in a therapeutically effective amount to a subject in need thereof to treat rheumatoid arthritis. | 2015-10-22 |
20150299253 | C4S PROTEOGLYCAN SPECIFIC TRANSPORTER MOLECULES - The present invention relates to isolated molecules, peptides, and polypeptides of specific consensus sequences or structures, and to compounds comprising or consisting of such molecules, peptides and polypeptides, which may act as transporter molecules that specifically recognize proteoglycans, in particular, chondroitin-4-sulfate (C4S). The isolated molecules, peptides, polypeptides and compounds of the invention may be conjugated or otherwise linked to a biologically active moiety (BAM). Thus the BAM conjugates allow the specific targeting and delivery of the BAM, which may be, for example, a peptide, chemical entity or nucleic acid, into the cytoplasm and/or nuclei of C4S expressing cells in vitro and in vivo. | 2015-10-22 |
20150299254 | NOVEL POLYMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME - Novel methods to prepare novel polymers are disclosed. Oxazolidinyl compounds according to formula IV: | 2015-10-22 |
20150299255 | COMPOSITIONS AND METHODS FOR MODULATING INNATE AND ADAPTIVE IMMUNE SYSTEMS - Compositions and methods for modulating the innate and adaptive immune systems in a subject. The compositions and methods may inhibit the function of inhibitory receptors and enhance activity of activating receptors. The method typically includes the steps of: administering to the subject a composition having a therapeutic peptide or multivalent polypeptide having multiple copies of the therapeutic peptide in an amount sufficient to increase activity of the immune system in the subject. Compositions may include a carrier; at least one agent selected from the group consisting of: an anti-inflammatory agent, a cytotoxic T cell proliferation agent, and/or a NK cell proliferation agent; and a selected therapeutic peptide or multivalent polypeptide. The compositions may also include an immunoglobulin admixed therewith to enhance passive immunoprotection. | 2015-10-22 |
20150299256 | ANTIBIOTIC PEPTIDES - The invention relates to a peptide or peptide derivative having the general formula: Sub | 2015-10-22 |
20150299257 | BIOACTIVE PEPTIDE COMPLEXES - The present invention refers to proteins and bioactive peptides with immunomodulating and antiviral activity. Present peptide complexes have three-dimensional structure and are described by the following structural formula (SEQ ID NO: 23): | 2015-10-22 |
20150299258 | Peptide for Inhibiting Vascular Endothelial Growth Factor Receptor - An object of the present invention is to provide a VEGFR2 inhibitor peptide having high specificity and available at a low cost. The present invention provides a peptide having the following amino acid sequence: | 2015-10-22 |
20150299259 | PEPTIDES FOR THE TREATMENT AND EARLY DIAGNOSIS OF ALZHEIMER'S DISEASE AND OTHER TAUOPATHIES - The present invention relates to novel tau protein aggregate-binding peptides, homologs, fragments, parts and polymers thereof and to the use thereof. | 2015-10-22 |
20150299260 | POLYPEPTIDE EXPRESSED IN THE STRATUM CORNEUM AND USE THEREOF - Polypeptides belonging to the family of late proteins of the cornified envelope (LCE), fragments of the polypeptide, isolated nucleotide sequences encoding the polypeptides, and cosmetic and/or pharmaceutical compositions containing such polypeptides are described. The polypeptides have cosmetic and/or therapeutic use to reinforce the barrier function of the epidermis, prevent and/or treat the signs of skin dryness and prevent and/or treat disorders of the barrier function or the weakening of the epidermis. | 2015-10-22 |
20150299261 | EPTIFIBATIDE PREPARATION METHOD - An Eptifibatide preparation method with product purity of more than 99.5%, the method comprising: using a solid phase polypeptide synthesis method to prepare eptifibatide resin, conducting acidolysis on the Eptifibatide resin to obtain a crude Eptifibatide linear peptide product, oxidizing to obtain a crude Eptifibatide product, purifying and exchanging salt to obtain an Eptifibatide finished product; the method using the solid phase polypeptide synthesis method to prepare the eptifibatide resin is: using a solid phase coupling synthesis method to sequentially splice a corresponding protective amino acid or a segment in the following sequence onto amino resin, and obtaining the Eptifibatide resin: X—Y-Trp(R | 2015-10-22 |
20150299262 | CYCLIC PEPTIDE AND PHARMACEUTICAL PRODUCT CONTAINING SAME - Provided is a novel compound which has excellent inhibitory activity for Aβ aggregation, and which is useful as a drug. | 2015-10-22 |
20150299263 | COMPLEX-FORMATION-MODULATING AGENTS AND USES THEREFOR - Disclosed are methods and agents for modulating proliferation, migration and/or survival of cells. More particularly, the present invention discloses molecules that have any one or more activities selected from: inhibiting binding of vitronectin to at least one vitronectin-binding partner selected from an IGF and IGFBP, inhibiting formation of a complex comprising vitronectin and at least one vitronectin-binding partner selected from an IGF and IGFBP, or inhibiting proliferation or survival of a hyperproliferative cell (e.g., a neoplastic cell or non-neoplastic cell), or inhibiting migration or invasion of a hyperproliferative cell (e.g., a neoplastic cell or a non-neoplastic cell). Additionally, the present invention discloses the use of these molecules in methods and compositions for treating or preventing hyperproliferative cell disorders including neoplastic (e.g., cancers such as epithelial cancers) and non-neoplastic disorders. | 2015-10-22 |
20150299264 | INHIBITION OF CARDIAC FIBROSIS IN MYOCARDIAL INFARCTION - The described invention provides a method for treating myocardial infarction (MI) in a subject comprising administering to the subject a therapeutic amount of a pharmaceutical composition comprising a polypeptide of amino sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or a functional equivalent thereof made from a fusion between a first polypeptide that is a cell permeable protein (CPP) selected from the group consisting of a polypeptide of amino acid sequence YARAAARQARA (SEQ ID NO: 2), WLRRIKAWLRRIKA (SEQ ID NO: 21), WLRRIKA (SEQ ID NO: 22), YGRKKRRQRRR (SEQ ID NO: 23), FAKLAARLYR (SEQ ID NO: 25), and KAFAKLAARLYR (SEQ ID NO: 26), and a second polypeptide that is a therapeutic domain (TD), and a pharmaceutically acceptable carrier. The described invention also provides a kit comprising a composition comprising at least one MK2 inhibitor peptide; a means for administering the composition; and a packaging material. | 2015-10-22 |
20150299265 | BINDING PROTEINS COMPRISING AT LEAST TWO REPEAT DOMAINS AGAINST HER2 - The present invention relates to a recombinant binding protein comprising at least a first and a second repeat domain, wherein each of said two repeat domains binds the extracellular region of HER2 and wherein said repeat domains are covalently linked. | 2015-10-22 |
20150299266 | BETA SHEET TAPES RIBBONS IN TISSUE ENGINEERING - There is described a material comprising tapes, ribbons, fibrils or fibres characterized in that each of the ribbons, fibrils or fibres have an antiparallel arrangement of peptides in a β-sheet tape-like substructure wherein the material comprises a pair of self assembling complementary polypeptides. | 2015-10-22 |
20150299267 | PR13.5 PROMOTER FOR ROBUST T-CELL AND ANTIBODY RESPONSES - The invention encompasses recombinant poxviruses, preferably modified Vaccinia Ankara (MVA) viruses, comprising a Pr13.5 promoter operably linked to a nucleotide sequence encoding an antigen and uses thereof. The invention is drawn to compositions and methods for the induction of strong CD8 T cell and antibody responses to a specific antigen(s) by administering one or more immunizations of the recombinant MVA to a mammal, preferably a human. | 2015-10-22 |
20150299268 | HIV-1 ENV-BINDING ANTIBODIES, FUSION PROTEINS, AND METHODS OF USE - Fusion proteins comprising a portion of the HIV-1 Env protein and ScFv of an enhancing antibody are disclosed that may serve in immunogenic formulations for vaccination against HIV-1 infection. A broadly neutralizing antibody and engineered bi-/tri-specific anti-HIV-1 antibodies that may serve in the prevention and/or treatment of HIV-1 infections in a subject are also disclosed, as well as methods of using the fusions proteins and antibodies. | 2015-10-22 |
20150299269 | INFLUENZA VACCINATION - Influenza viruses have traditionally been administered by intramuscular injection. The invention is based on the idea of using alternative routes of delivery for influenza vaccines, more specifically routes that do not require as large a dose of antigen. Delivery of influenza antigen to the Langerhans cells is the route of choice according to the invention. This route has been found to be particularly useful for vaccinating patients who are naïve to influenza virus (i.e. have not previously mounted an immune response to an influenza virus), which means that it is advantageous for immunising young children. | 2015-10-22 |
20150299270 | POLYVALENT INFLUENZA VIRUS-LIKE PARTICLE (VLP) COMPOSITIONS - Polyvalent influenza virus-like particles (VLPs) comprising influenza antigenic polypeptides are described. Also described are compositions comprising these polyvalent VLPs as well as methods of making and using these VLPs. | 2015-10-22 |
20150299271 | TREATING CANCER WITH VIRAL NUCLEIC ACID - This document provides methods and materials related to the use of nucleic acid coding for viruses to reduce the number of viable cancer cells within a mammal. For example, methods for using infectious nucleic acid to treat cancer, engineered viral nucleic acid, methods for making engineered viral nucleic acid, methods for identifying infectious nucleic acid for treating cancer, methods and materials for controlling virus-mediated cell lysis, and methods and materials for assessing the control of virus-mediated cell lysis are provided. | 2015-10-22 |
20150299272 | RECOMBINANT POLYPEPTIDE - The invention provides a chaperone/usher family polymer comprising at least one chaperone/usher family polypeptide monomer, wherein said at least one chaperone/usher family polypeptide monomer comprises an exogenous bioactive sequence. | 2015-10-22 |
20150299273 | AXMI335 TOXIN GENE AND METHODS FOR ITS USE - Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a toxin polypeptide are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also comprise transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated toxin nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed, and antibodies specifically binding to those amino acid sequences. In particular, the present invention provides for isolated nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequence shown in SEQ ID NO:2 or 4, or the nucleotide sequence set forth in SEQ ID NO: 1 or 3, as well as variants and fragments thereof. | 2015-10-22 |
20150299274 | AXMI-115, AXMI-113, AXMI-005, AXMI-163 AND AXMI-184: INSECTICIDAL PROTEINS AND METHODS FOR THEIR USE - Compositions and methods for conferring insecticidal activity to host cells are provided. Compositions comprising a coding sequence for a delta-endotoxin polypeptide are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in host cells. Compositions also comprise transformed host cells. In particular, isolated delta-endotoxin nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed, and antibodies specifically binding to those amino acid sequences. In particular, the present invention provides for isolated nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequence shown in SEQ ID NO:4, 5, 6, 13, or 14, or the nucleotide sequence set forth in SEQ ID NO:1, 2, 3, 11, or 12, as well as variants and fragments thereof. | 2015-10-22 |
20150299275 | SEPARATION PROCESSES FOR SOY PROTEIN - The invention provides a process for the separation of soy protein. The process begins with an aqueous extract or solution of soy protein, which is passed through at least one expanded bed absorption (EBA) process. The EBA process comprises contacting the aqueous extract or solution of soy protein with at least one adsorbent resin, said adsorbent resin comprising at least one ligand (L1 or L2), having particular chemical structures. Proteins of interest (e.g. trypsin inhibitor (TI) protein or beta-conglycinin) are isolated by eluting them from said adsorbent resin. The invention also provides various novel protein compositions obtainable via the method of the invention. | 2015-10-22 |
20150299276 | Alpha-CONOTOXIN PEPTIDE, PHARMACEUTICAL COMPOSITION AND USE THEREOF - The present invention provides a novel α-conotoxin peptide, pharmaceutical composition and use thereof. The present invention further provides a propeptide of the conotoxin peptide, a nucleic acid construct, expression vector and transformed cell of the conotoxin peptide as well as a fused protein of the conotoxin peptide. The present invention discloses a method for blocking acetylcholine receptors as well as a use of the conotoxin peptide in the manufacture of a medicament. The α-conotoxin peptide of the present invention can specifically block acetylcholine receptor (nAChRs, such as α3β2 nAChRs, α6/α3β2β3 nAChR or α3β4 nAChR or α6/α3β4 nAChR), has activity for treatment of neuralgia, addiction, Parkinson's disease, dementia, schizophrenia, cancers, and can be used in the manufacture of a medicament for analgesia and smoking cessation and drug-withdrawal, a medicament for treatment of mental diseases and cancers, as well as a tool drug for neurosciences. | 2015-10-22 |
20150299277 | AGENT FOR TREATING OR PREVENTING SYSTEMIC INFLAMMATORY RESPONSE SYNDROME - The present invention provides a therapeutic or prophylactic agent for systemic inflammatory response syndrome (SIRS), which contains a polypeptide comprising an amino acid sequence the same or substantially the same as the amino acid sequence of the N-terminal domain of pentraxin 3 capable of binding to histone to form a polypeptide aggregate, or a pharmacologically acceptable salt thereof. The present invention also provides a reagent for quantification and a quantification method of histone, which utilize the polypeptide or a pharmacologically acceptable salt thereof. Furthermore, the present invention provides a polypeptide aggregate containing the polypeptide or a pharmacologically acceptable salt thereof and histone and a production method thereof. | 2015-10-22 |
20150299279 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISORDERS AND ALZHEIMER'S DISEASE AND IMPROVING NORMAL MEMORY - The disclosure relates generally to neurodegenerative disorders and more specifically to a group of presenilin/G-protein/c-src binding polypeptides and methods of use for modulating signaling and progression of Alzheimer's disease. | 2015-10-22 |
20150299280 | MEDICAL TREATMENT USE OF CELL-MEMBRANE-PERMEABLE FIBROBLAST GROWTH FACTOR - The present invention relates to a chimeric protein formed by fusing a CPP containing a CPP-C domain in any of an FGF11, FGF12, FGF13, and FGF14 to an FGF1 or an FGF2, or DNA molecules that contain DNA sequences coding the FGF1 or the FGF2 and DNA sequences coding a CPP-C or vectors containing these DNA sequences. These chimeric protein, DNA molecules, or vectors can be used for a medicine or a method of treatment effective to a tissue on which an expression of an FGFR is low or becomes low due to any cause, a medicine or a method of treatment that can further dynamize bioactivity of the FGF1 or the FGF2 via the FGFR, or a medicine or a method of treatment that protects a stem cell against an influence from radiation exposure, a chemotherapy, or a similar treatment. | 2015-10-22 |
20150299281 | GIP-GLP-1 DUAL AGONIST COMPOUNDS AND METHODS - The present invention relates to truncated GIP analogues which comprise one or more substitutions as compared to wild-type GIP and which may have the property of an altered, preferably increased GLP-1 activity, e.g. as assessed in in vitro efficacy assays. The invention provides GIP-GLP-1 dual agonist compounds and associated methods. | 2015-10-22 |
20150299282 | A COMPOSITION FOR TREATING DIABETES OR DIABESITY COMPRISING OXYNTOMODULIN ANALOG - Disclosed are a composition for preventing or treating diabetes, diabesity or diabetic complications, containing an oxyntomodulin analog as an active ingredient and a method for treating diabetes, diabesity or diabetic complications, including administering a pharmaceutically effective amount of an oxyntomodulin analog to a subject. The oxyntomodulin analog shows a greater activity to activate a GLP-1 receptor and a glucagon receptor, than native oxyntomodulin. The oxyntomodulin analog induces an expansion of beta-cells and increases insulin secretion, thereby reducing blood glucose levels that were increased due to a high-calorie and high-fat diet. The oxyntomodulin analog induces decreases in a body weight and appetite to improve insulin sensitivity and is useful in maintaining normal blood glucose levels. | 2015-10-22 |
20150299283 | NOVEL PEPTIDE AND APPLICATION THEREOF - An object of the present invention is to discover a novel component of the renin-angiotensin system (RAS) and to provide the same as a novel biomarker of a cardiovascular disease or a renal disease. This invention provides a novel peptide associated with the renin-angiotensin system comprising the amino acid sequence as shown in SEQ ID NO: 1 or an amino acid sequence derived therefrom by deletion, substitution, or addition of one to several amino acids other than the asparagine residue at position 14 and an N-linked glycan added thereto at the asparagine residue at position 14. With the use of such peptide as a biomarker, a renal disease or a cardiovascular disease can be diagnosed at an early stage in a simple manner without imposing burdens on a subject. | 2015-10-22 |
20150299284 | NATRIURETIC POLYPEPTIDES - This document provides methods and materials related to natriuretic polypeptides and the use of natriuretic polypeptides to treat cardiovascular and/or renal conditions. For example, chimeric polypeptides having at least one amino acid segment (e.g., N-terminus tail, ring structure, C-terminus tail, or a combination thereof) of a natriuretic peptide (e.g., ANP, BNP, CNP, URO, or DNP) and an amino acid segment of an angiotensin polypeptide (e.g., Ang-(1-7)) are provided. | 2015-10-22 |
20150299285 | CTP-BASED INSULIN ANALOGS FOR TREATMENT OF DIABETES - Insulin analogs comprising a non-native glycosylation site sequence are provided having high potency and specificity for the insulin receptor. In one embodiment a peptide sequence of greater than 18 amino acids is used as a linking moiety to link human insulin A and B chains, or analogs or derivatives thereof, to provide high potency single chain insulin analogs. In one embodiment the linking moiety comprises one or more glycosylation sites. Also disclosed are prodrug and conjugate derivatives of the insulin analogs. | 2015-10-22 |
20150299286 | GLUTAMIC ACID-STABILIZED INSULIN ANALOGUES - An insulin analogue comprises a B-chain polypeptide containing the acidic two-residue extension GluB31-GluB32, and optionally an A-chain polypeptide containing acidic substitution GluA8, and additionally optionally a non-standard modification of PheB24. The analogue may also contain additional B-chain substitutions known in the art to enhance the rate of absorption of an insulin analogue formulation following subcutaneous injection or infusion. The analogue may be an analogue of a mammalian insulin, such as human insulin. A nucleic acid encoding such an insulin analogue is also provided. A method of treating a patient comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to a patient. The analogue may be administered at a high concentration while maintaining fast-acting properties. A method of semi-synthesis using an unprotected octapeptide by means of modification of an endogenous tryptic site by non-standard amino-acid substitutions. | 2015-10-22 |
20150299287 | O-LINKED CARBOHYDRATE-MODIFIED INSULIN ANALOGUES - An insulin analogue comprises an insulin B-chain polypeptide modified with an O-linked monosaccaride pyranoside adduct at the side chain of residue B27 or an O-linked monosaccaride pyranoside adduct at the side chain of residue B30, or both, where the positions are recited relative to human insulin. The monosaccaride may be a manopyranoside, an N-acetyl-galactopyranoside, or a glucopyranoside. The insulin analogue may additionally comprise containing a foreshortened B-chain polypeptide lacking residues B1-B3, an extension of 1 or 2 Glu residues on the carboxy terminal end of the B-chain polypeptide, an extension of ornithine at the carboxy-terminal end of the B-chain, the substitutions Lys at position B28 and Pro at position B29, an ornithine substitution at position B29, or combinations thereof. The analogue may be an analogue of a mammalian insulin, such as human insulin. A method of treating a patient comprises administering a physiologically effective amount of the insulin analogue. | 2015-10-22 |
20150299288 | Modified Insulin Polypeptides and Their Uses - Modified insulin polypeptides and their uses thereof are provided | 2015-10-22 |
20150299289 | DEVELOPMENT OF HBV-AND/OR HDV-SUSCEPTIBLE CELLS, CELL LINES AND NON-HUMAN ANIMALS - The present invention relates to a novel Hepatitis B virus (HBV) and/or Hepatitis D virus (HDV) receptor and its use for the development of cells, cell lines and non-human animals that are susceptible to HBV and/or HDV infection and can be used for immunological studies and/or for the screening of drugs, post-entry restriction factors and host dependency factors. It further relates to the use of the receptor for the identification of compounds useful in the treatment of HBV and/or HDV infection. | 2015-10-22 |
20150299290 | IMMUNOGENIC VACCINE - A glycolipopeptide comprising a carbohydrate component, a lipid component, and a MUC1 peptide component that induces both a humoral and a cellular immune response for use as a therapeutic or prophylactic vaccine. | 2015-10-22 |
20150299291 | cDNA-DERIVED NUCLEIC ACIDS ENCODING RED-SHIFTED CHANNELRHODOPSINS - Methods and compositions are used to identify and characterize new channelrhodopsins derived from algae and several of which are red-shifted. The rhodopsin domain of these red-shifted channelrhodopsins can be cloned and expressed in mammalian systems and used in optogenetic applications and as therapeutic agents. Also provided are methods and compositions for use in red-shifting the absorbance maxima of channelrhodopsins in order to improve their utility for use in vivo. | 2015-10-22 |
20150299292 | METHODS AND COMPOSITIONS FOR MODULATING TOSO ACTIVITY - The present invention is further directed to methods and compositions for modulating the activity of the Toso protein. The invention further encompasses treatment of disorders associated with inflammation, autoimmune disorders, and cancer using compositions that include a soluble Toso protein. | 2015-10-22 |
20150299293 | T1R TASTE RECEPTORS AND GENES ENCODING SAME - Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in taste signaling, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular tastant in a mammal are also described, as are methods for generating novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes. Further, methods for stimulating or blocking taste perception in a mammal are also disclosed. | 2015-10-22 |
20150299294 | NEW FUSION PROTEINS FOR THE TREATMENT OF ALLERGIC DISEASES - The present invention relates to a fusion protein comprising a first peptide and a second peptide linked together with a linker, wherein the first peptide is an allergen and the second peptide is a targeting unit and the targeting unit is a FGL-2 C-terminal peptide according to SEQ ID no 1. Provided herein are also uses of said fusion protein as a vaccine for treating allergy, such as shrimp, peanut or mite allergy, as well as a vaccine composition and methods for producing such fusion proteins. | 2015-10-22 |
20150299295 | Collagen Fibrillar Construction - Methods and compositions are described for organizing collagen into fibrillar networks, e.g, short and long-range organization. Collagen produced by the disclosed methods can be used for tissue engineering. | 2015-10-22 |
20150299296 | FCgammaRIIB-SPECIFIC FC REGION VARIANT - An objective of the present invention is to provide an Fc region variant with enhanced FcγRIIb-binding activity, and/or enhanced binding selectivity to FcγRIIb compared to FcγRIIa (type R), as compared to those of a polypeptide containing an Fc region to which an amino acid alteration(s) has not been introduced; a polypeptide which includes the Fc region variant; a pharmaceutical composition containing the polypeptide; preventing therapeutic or preventive agent for immunological inflammatory diseases that includes the pharmaceutical composition; a production method thereof; and a method of enhancing FcγRIIb-binding activity and also enhancing binding selectivity to FcγRIIb compared to FcγRIIa (type R). | 2015-10-22 |
20150299297 | Passive Immunisation Against Influenza, In Particular H5N1 - The invention relates to a composition comprising immunoglobulins specific to influenza virus and produced through immunization of a producer animal, for use as a medicament for the passive immunisation of a human against an infection by an influenza virus, wherein the medicament is administered to the human in at least 1 dose before exposition or risk of exposition to an influenza virus and/or after exposition or risk of exposition to an influenza virus, and wherein the overall amount administered to the human in one or more doses is at least 20 μg of immunoglobulins per kg body weight. When the composition is for use after exposition or risk of exposition to an influenza virus, it is preferably administered to the human in at least 2 doses after exposition or risk of exposition to an influenza virus. | 2015-10-22 |
20150299298 | BINDING MOIETIES FOR BIOFILM REMEDIATION - Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies suitable for administration to a selected species and decoy nucleic acids. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described. | 2015-10-22 |
20150299299 | ANTIBODIES TO AMYLOID BETA - Antibody for human amyloid beta. Antibody selectively binds human amyloid beta 42 peptide over human amyloid beta 40 peptide. Antibodies specific for amyloid beta 42 as therapeutic agents for binding amyloid beta 42 peptide and treating conditions associated with amyloidosis, such as Alzheimer's disease. | 2015-10-22 |
20150299300 | METHOD OF TREATING CANCER - A method for inducing apoptosis of a neoplastic cell expressing C3aR or C5aR includes administering at least one complement antagonist to the cell so that the at least one complement antagonist substantially reduces or inhibits the activity of protein kinase B in the neoplastic cell. | 2015-10-22 |
20150299301 | POLYPEPTIDES AND POLYPEPTIDE CONSTRUCTS COMPRISING SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST VON WILLEBRAND FACTOR - The present invention relates to polypeptides comprising at least one single domain antibody directed against vWF, vWF A1 domain, A1 domain of activated vWF, vWF A3 domain, gpIb and/or collagen, homologues of said polypeptides, and/or functional portions of said polypeptides, for the treatment for conditions which require a modulation of platelet-mediated aggregation and which overcomes the problems of the prior art. A further aspect of the invention is methods of production of said polypeptides, methods to coat devices with such polypeptides used in medical procedures (e.g. PCTA, stenting), methods and kits for screening for agents that modulate platelet-mediated aggregation and kits for the diagnosis of diseases related to platelet-mediated aggregation. | 2015-10-22 |
20150299302 | Adult Stem Cells/Progenitor Cells and Stem Cell Proteins for Treatment of Eye Injuries and Diseases - The present invention encompasses methods and compositions for treating an ocular disease, disorder or condition in a mammal. The invention includes a population of mesenchymal stromal cells that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties. The invention includes administration of TSG-6, STC-1, or a combination thereof to the ocular as a treatment for an ocular disease, disorder or condition in a mammal. | 2015-10-22 |
20150299303 | HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF - The present invention provides antibodies that bind to the cat allergen, Fel d1, compositions comprising the antibodies, nucleic acids encoding the antibodies and methods of use of the antibodies. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Fel d1. The antibodies of the invention are useful for binding to the Fel d1 allergen in vivo, thus preventing binding of the Fel d1 allergen to pre-formed IgE on the surface of mast cells or basophils. In doing so, the antibodies act to prevent the release of histamine and other inflammatory mediators from mast cells and/or basophils, thus ameliorating the untoward response to the cat allergen in sensitized individuals. The antibodies of the invention may also be useful for diagnostic purposes to determine if a patient is allergic to the Fel d1 cat allergen. | 2015-10-22 |
20150299304 | Modulation of the VPS10P-Domain Receptors for the Treatment of Cardiovascular Disease - The present invention relates to methods for modulating the activity of one or more Vps10p-domain receptors selected from the group consisting of Sortilin, SorLA, SorCS1, SorCS2 and SorCS3, in an animal and methods for preparation of a medicament for the treatment of abnormal plasma lipid concentrations and associated diseases and/or disorders. The modulation is carried out by inhibiting or promoting the binding of ligands to the Vps10p-domain receptor. In vitro and in vivo methods for screening for agents capable of modulation of said Vps10p-domain receptor activity are also provided. The invention furthermore relates to methods of altering expression of said receptors in vivo. | 2015-10-22 |
20150299305 | ANTI-C5 ANTIBODIES HAVING IMPROVED PHARMACOKINETICS - The disclosure provides antibodies that are useful for among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human. | 2015-10-22 |